These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 38027160)
1. Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer. Chen X; Pan Y; Wang Q; Ren C; Li M; Hao X; Xie L; Liu X Front Endocrinol (Lausanne); 2023; 14():1225033. PubMed ID: 38027160 [TBL] [Abstract][Full Text] [Related]
2. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis. Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712 [TBL] [Abstract][Full Text] [Related]
4. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE; Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602 [TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis. Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752 [TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With Fallah J; Xu J; Weinstock C; Brave MH; Bloomquist E; Fiero MH; Schaefer T; Pathak A; Abukhdeir A; Bhatnagar V; Chiu HJ; Ricks T; John C; Hamed S; Lee C; Pierce WF; Kalavar S; Philip R; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman D J Clin Oncol; 2024 Feb; 42(5):605-613. PubMed ID: 38127780 [TBL] [Abstract][Full Text] [Related]
7. Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study. Xie J; Guo H; Dong B; Chen W; Jin C; Xu Q; Ding L; Liu W; Dong S; Zhao T; Yu Y; Guo C; Yao X; Peng B; Yang B Eur Urol Oncol; 2024 Oct; 7(5):1088-1096. PubMed ID: 38458891 [TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830 [TBL] [Abstract][Full Text] [Related]
9. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Zhou ZR; Liu SX; Zhang TS; Xia J; Li B Asian Pac J Cancer Prev; 2014; 15(3):1313-20. PubMed ID: 24606458 [TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Ai J; Jian L; Wen X; Huo X; Yang X; Jiang J; Zhang T Clin Transl Oncol; 2024 Oct; 26(10):2559-2571. PubMed ID: 38750344 [TBL] [Abstract][Full Text] [Related]
11. Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer. De Santis M; Breijo SM; Robinson P; Capone C; Pascoe K; Van Sanden S; Hashim M; Trevisan M; Daly C; Reitsma F; van Beekhuizen S; Ruan H; Heeg B; Verzoni E Adv Ther; 2024 Aug; 41(8):3039-3058. PubMed ID: 38958846 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Luo Z; Zhu B; Xu H; Chen L; Song X; Wang Y; Wang R; Zheng J; Qiu Y; Yang J; Shi Y Front Oncol; 2023; 13():1265276. PubMed ID: 37869079 [TBL] [Abstract][Full Text] [Related]
13. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390 [TBL] [Abstract][Full Text] [Related]
14. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis. Huang Y; He H; Liang L; Zhang Y; Peng K; Wang Y; Wu J; Long X; Kairemo K; Goldberg H; Mendez LC; Gu D Chin Clin Oncol; 2024 Aug; 13(4):64. PubMed ID: 39238347 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. Antonarakis ES; Park SH; Goh JC; Shin SJ; Lee JL; Mehra N; McDermott R; Sala-Gonzalez N; Fong PC; Greil R; Retz M; Sade JP; Yanez P; Huang YH; Begbie SD; Gafanov RA; De Santis M; Rosenbaum E; Kolinsky MP; Rey F; Chiu KY; Roubaud G; Kramer G; Sumitomo M; Massari F; Suzuki H; Qiu P; Zhang J; Kim J; Poehlein CH; Yu EY J Clin Oncol; 2023 Aug; 41(22):3839-3850. PubMed ID: 37290035 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Clarke NW; Armstrong AJ; Oya M; Shore N; Procopio G; Daniel Guedes J; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Young Joung J; Sugimoto M; Sartor O; Poehlein C; McGuinness D; Degboe A; Saad F Eur Urol Oncol; 2024 Oct; ():. PubMed ID: 39384451 [TBL] [Abstract][Full Text] [Related]
20. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. Kim JW; McKay RR; Radke MR; Zhao S; Taplin ME; Davis NB; Monk P; Appleman LJ; Lara PN; Vaishampayan UN; Zhang J; Paul AK; Bubley G; Van Allen EM; Unlu S; Huang Y; Loda M; Shapiro GI; Glazer PM; LoRusso PM; Ivy SP; Shyr Y; Swisher EM; Petrylak DP J Clin Oncol; 2023 Feb; 41(4):871-880. PubMed ID: 36256912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]